Cyclin-Dependent Kinases 4/6 Inhibition in Glioblastoma: From Molecular Rationale to Therapeutic Challenges and Opportunities
Cancers · 06.11.2026 · 18 (21) · 3578
DOI: 10.3390/cancers18213578 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.11.2026. Verfasst von Ankush Chandra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Houston, Houston, TX 77030, USA. Die Arbeit nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Glioblastoma (GBM) remains the most lethal primary malignant brain tumor in adults despite maximal resection, radiotherapy, and temozolomide. The cyclin D-CDK4/6-RB axis plays a significant role in cell cycle regulation and is amongst the most frequently dysregulated pathways in many cancers including GBM, thus providing a strong rationale for using CDK4/6 inhibitors (CDK4/6is) in treating this tumor. While palbociclib, ribociclib, and abemaciclib are FDA-approved to treat hormone positive breast cancer, they have demonstrated robust target engagement and efficacy in preclinical studies in GBM. However, clinical trial data has been modest, highlighting a major gap between biological rationale and therapeutic efficacy in the clinical setting. In this comprehensive review, we examine the molecular functions of CDK4/6 in GBM, delve into the pharmacologic properties of approved and emerging inhibitors, explore mechanisms of drug resistance and discuss combination strategies, clinical experience till date, and potential biomarkers for ideal patient selection. Future progress will likely require CNS-active inhibitors, rational combination therapies, functional biomarker selection, and early confirmation of adequate tumor drug exposure and pathway suppression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Houston, Houston, TX 77030, USA.
- Department of Cell Biology and Genetics, College of Medicine, Texas A&M University, College Station, TX 77843, USA.
- Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
- Department of Neurology, Virginia Tech Carilion, Roanoke, VA 24016, USA.
ORCID-Profile: Ankush Chandra, Mariana K Najjar, Phi-Long Tran
Förderung
- United States Department of Defense
- NIH HHS
- NCI NIH HHS
- METAvivor
- NINDS NIH HHS
- National Institutes of Health
- Department of Defense
Zitieren
APA
Chandra, A., Najjar, M. K., Tran, P. L., Cha, J., Morales, M., & Lo, H. W. (2026). Cyclin-Dependent Kinases 4/6 Inhibition in Glioblastoma: From Molecular Rationale to Therapeutic Challenges and Opportunities. Cancers, 18(21), 3578. https://doi.org/10.3390/cancers18213578
Vancouver
Chandra A, Najjar MK, Tran PL, Cha J, Morales M, Lo HW. Cyclin-Dependent Kinases 4/6 Inhibition in Glioblastoma: From Molecular Rationale to Therapeutic Challenges and Opportunities. Cancers. 2026;18(21):3578. doi:10.3390/cancers18213578
BibTeX
@article{Chandra2026,
author = {Chandra, Ankush and Najjar, Mariana K and Tran, Phi-Long and Cha, Joshua and Morales, Marc and Lo, Hui-Wen},
title = {Cyclin-Dependent Kinases 4/6 Inhibition in Glioblastoma: From Molecular Rationale to Therapeutic Challenges and Opportunities},
journal = {Cancers},
year = {2026},
volume = {18},
number = {21},
pages = {3578},
doi = {10.3390/cancers18213578}
}
EUVIMED